Lumbar interbody fusion with porous biphasic calcium phosphate enhanced by recombinant bone morphogenetic protein-2/silk fibroin sustained-released microsphere: an experimental study on sheep model

Journal of Materials Science: Materials in Medicine

Volumn 26, Issue 3, 2015, Pages

  Chen, Liang ^a   Liu, Hai Long ^a   Gu, Yong ^a   Feng, Yu ^a   Yang, Hui Lin ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM PHOSPHATE; MICROSPHERES; RECOMBINANT PROTEINS; TISSUE REGENERATION;

BIOMECHANICAL TESTING; BIPHASIC CALCIUM PHOSPHATES; BONE REGENERATION; BONE SUBSTITUTES; LUMBAR INTERBODY FUSION; QUANTITATIVE CT; RECOMBINANT BONE MORPHOGENETIC PROTEIN-2; SUSTAINED RELEASE;

COMPUTERIZED TOMOGRAPHY;

BIPHASIC CALCIUM PHOSPHATE; CALCIUM PHOSPHATE; MICROSPHERE; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; SILK FIBROIN; UNCLASSIFIED DRUG; BONE MORPHOGENETIC PROTEIN 2; FIBROIN; RECOMBINANT PROTEIN; SILK;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLOGICAL ACTIVITY; BIOMECHANICS; BONE REGENERATION; COMPUTER ASSISTED TOMOGRAPHY; CONFORMATION; CONTROLLED STUDY; DRUG EFFICACY; EXPERIMENTAL SHEEP; FOLLOW UP; HISTOLOGY; IN VITRO STUDY; INFRARED SPECTROSCOPY; LOW DRUG DOSE; LUMBAR INTERBODY FUSION; LUMBAR SPINE; NERVE ENDING; NEUROLOGIC DISEASE; NONHUMAN; OSSIFICATION; PALPATION; POROSITY; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; SPINE FUSION; SURFACE PROPERTY; SUSTAINED DRUG RELEASE; ANIMAL; CHEMISTRY; LUMBAR VERTEBRA; SHEEP; SURGERY;

OVIS ARIES;

ANIMALS; BONE MORPHOGENETIC PROTEIN 2; CALCIUM PHOSPHATES; FIBROINS; LUMBAR VERTEBRAE; MICROSPHERES; MODELS, ANIMAL; RECOMBINANT PROTEINS; SHEEP; SILK; SPINAL FUSION;

EID: 84923352854     PISSN: 09574530     EISSN: 15734838     Source Type: Journal    
DOI: 10.1007/s10856-015-5463-x     Document Type: Article

References (38)

1. Ito Z, Imagama S, Kanemura T, Hachiya Y, Miura Y, Kamiya M, et al. Bone union rate with autologous iliac bone versus local bone graft posterior in lumbar interbody fusion (PLIF): a multicenter study. Eur Spine J. 2013;22(5):1158–63.
2. Perez-Cruet MJ, Hussain NS, White GZ, Begun EM, Collins RA, Fahim DK, et al. Quality-of-life outcomes with minimally invasive transforaminal lumbar interbody fusion based on long-term analysis of 304 consecutive patients. Spine. 2014;39(3):E191–8.
3. Hao Y, Deng S, Li J, Ma Y. Using of transforaminal lumbar interbody fusion in lumbar revision surgery. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2011;25(1):87–90.
4. Lykissas MG, Aichmair A. Current concepts on spinal arthrodesis in degenerative disorders of the lumbar spine. World J Clin Cases. 2013;1(1):4–12.
5. Radcliff K, Hwang R, Hilibrand A, Smith HE, Gruskay J, Lurie JD, et al. The effect of iliac crest autograft on the outcome of fusion in the setting of degenerative spondylolisthesis: a subgroup analysis of the Spine Patient Outcomes Research Trial (SPORT). J Bone Joint Surg Am. 2012;94(18):1685–92.
6. Hoffmann MF, Jones CB, Sietsema DL. Adjuncts in posterior lumbar spine fusion: comparison of complications and efficacy. Arch Orthop Trauma Surg. 2012;132(8):1105–10.
7. Kager AN, Marks M, Bastrom T, Newton PO. Morbidity of iliac crest bone graft harvesting in adolescent deformity surgery. J Pediatr Orthop. 2006;26(1):132–4.
8. Niu CC, Tsai TT, Fu TS, Lai PL, Chen LH, Chen WJ. A comparison of posterolateral lumbar fusion comparing autograft, autogenous laminectomy bone with bone marrow aspirate, and calcium sulphate with bone marrow aspirate: a prospective randomized study. Spine. 2009;34(25):2715–9.
9. Epstein NE. An analysis of noninstrumented posterolateral lumbar fusions performed in predominantly geriatric patients using lamina autograft and beta tricalcium phosphate. Spine J. 2008;8(6):882–7.
10. Witoon N, Tangviriyapaiboon T. Clinical and radiological outcomes of segmental spinal fusion in transforaminal lumbar interbody fusion with spinous process tricortical autograft. Asian Spine J. 2014;8(2):170–6.
11. Mobbs RJ, Chung M, Rao PJ. Bone graft substitutes for anterior lumbar interbody fusion. Orthop Surg. 2013;5(2):77–85.
12. Ehrler DM, Vaccaro AR. The use of allograft bone in lumbar spine surgery. Clin Orthop Relat Res. 2000;371:38–45.
13. Grabowski G, Cornett CA. Bone graft and bone graft substitutes in spine surgery: current concepts and controversies. J Am Acad Orthop Surg. 2013;21(1):51–60.
14. Fischer CR, Cassilly R, Cantor W, Edusei E, Hammouri Q, Errico T. A systematic review of comparative studies on bone graft alternatives for common spine fusion procedures. Eur Spine J. 2013;22(6):1423–35.
15. Even J, Eskander M, Kang J. Bone morphogenetic protein in spine surgery: current and future uses. J Am Acad Orthop Surg. 2012;20(9):547–52.
16. Shen J, Li Y, Zuo Y, Zou Q, Cheng L, Zhang L, et al. Characterization and cytocompatibility of biphasic calcium phosphate/polyamide 6 scaffolds for bone regeneration. J Biomed Mater Res B Appl Biomater. 2010;95(2):330–8.
17. Li B, Liao X, Zheng L, Zhu X, Wang Z, Fan H, et al. Effect of nanostructure on osteoinduction of porous biphasic calcium phosphate ceramics. Acta Biomater. 2012;8(10):3794–804.
18. Jang JW, Yun JH, Lee KI, Jang JW, Jung UW, Kim CS, et al. Osteoinductive activity of biphasic calcium phosphate with different rhBMP-2 doses in rats. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012;113(4):480–7.
19. Alam MI, Asahina I, Ohmamiuda K, Takahashi K, Yokota S, Enomoto S. Evaluation of ceramics composed of different hydroxyapatite to tricalcium phosphate ratios as carriers for rhBMP-2. Biomaterials. 2001;22(12):1643–51.
20. Alam I, Asahina I, Ohmamiuda K, Enomoto S. Comparative study of biphasic calcium phosphate ceramics impregnated with rhBMP-2 as bone substitutes. J Biomed Mater Res. 2001;54(1):129–38.
21. Noshi T, Yoshikawa T, Dohi Y, Ikeuchi M, Horiuchi K, Ichijima K, et al. Recombinant human bone morphogenetic protein-2 potentiates the in vivo osteogenic ability of marrow/hydroxyapatite composites. Artif Organs. 2001;25:201–8.
22. Bessa PC, Balmayor ER, Azevedo HS, Nürnberger S, Casal M, van Griensven M, et al. Silk fibroin microparticles as carriers for delivery of human recombinant BMPs. Physical characterization and drug release. J Tissue Eng Regen Med. 2010;4(5):349–55.
23. Bessa PC, Balmayor ER, Hartinger J, Zanoni G, Dopler D, Meinl A, et al. Silk fibroin microparticles as carriers for delivery of human recombinant bone morphogenetic protein-2: in vitro and in vivo bioactivity. Tissue Eng Part C Methods. 2010;16(5):937–46.
24. Chen L, Gu Y, Feng Y, Zhu XS, Wang CZ, Liu HL, et al. Bioactivity of porous biphasic calcium phosphate enhanced by recombinant human bone morphogenetic protein 2/silk fibroin microsphere. J Mater Sci Mater Med. 2014;25(7):1709–19.
25. Gu Y, Chen L, Yang HL, Luo ZP, Tang TS. Evaluation of an injectable silk fibroin enhanced calcium phosphate cement loaded with human recombinant bone morphogenetic protein-2 in ovine lumbar interbody fusion. J Biomed Mater Res A. 2011;97(2):177–85.
26. Smucker JD, Bobst JA, Petersen EB, Nepola JV, Fredericks DC. B2A peptide on ceramic granules enhance posterolateral spinal fusion in rabbits compared with autograft. Spine. 2008;33(12):1324–9.
27. Mobbs RJ, Chau AM, Durmush D. Biphasic calcium phosphate contained within a polyetheretherketone cage with and without plating for anterior cervical discectomy and fusion. Orthop Surg. 2012;4(3):156–65.
28. Fujibayashi S, Shikata J, Tanaka C, Matsushita M, Nakamura T. Lumbar posterolateral fusion with biphasic BCP. J Spinal Disord. 2001;14(3):214–21.
29. Choi Y, Lee JS, Kim YJ, Kim MS, Choi SH, Cho KS, et al. Recombinant human bone morphogenetic protein-2 stimulates the osteogenic potential of the Schneiderian membrane: a histometric analysis in rabbits. Tissue Eng Part A. 2013;19(17–18):1994–2004.
30. Hänseler P, Ehrbar M, Kruse A, Fischer E, Schibli R, Ghayor C, et al. Delivery of BMP-2 by two clinically available apatite materials: In vitro and in vivo comparison. J Biomed Mater Res A. 2014;103:628–38.
31. Kim S, Jung UW, Lee YK, Choi SH. Effects of biphasic calcium phosphate bone substitute on circumferential bone defects around dental implants in dogs. Int J Oral Maxillofac Implants. 2011;26(2):265–73.
32. Lu SX, Fiorini T, Lee J, Prasad HS, Buxton AN, Bisch FC, et al. Evaluation of a compression resistant matrix for recombinant human bone morphogenetic protein-2. J Clin Periodontol. 2013;40(7):688–97.
33. Dimar JR, Glassman SD, Burkus KJ, et al. Clinical outcomes and fusion success at 2 years of single-level instrumented posterolateral fusions with recombinant human bone morphogenetic protein-2/compression resistant matrix versus iliac crest bone graft. Spine. 2006;31:2534–40.
34. Cooperman L, Michaeli D. The immunogenicity of injectable collagen. II. A retrospective review of seventy-two tested and treated patients. J Am Acad Dermatol. 1984;10(4):647–51.
35. Numata K, Kaplan DL. Silk-based delivery systems of bioactive molecules. Adv Drug Deliv Rev. 2010;62(15):1497–508.
36. Solchaga LA, Hee CK, Aguiar DJ, Ratliff J, Turner AS, Seim HB 3rd, et al. Augment bone graft products compare favorably with autologous bone graft in an ovine model of lumbarinter body spine fusion. Spine. 2012;37(8):E461–7.
37. Fu R, Selph S, McDonagh M, Peterson K, Tiwari A, Chou R, et al. Effectiveness and harms of recombinant human bone morphogenetic protein-2 in spine fusion: a systematic review and meta-analysis. Ann Intern Med. 2013;158(12):890–2.
38. Barnes B, Boden SD, Louis-Ugbo J, Tomak PR, Park JS, Park MS, et al. Lower dose of rhBMP-2 achieves spine fusion when combined with an osteoconductive bulking agent in non-human primates. Spine. 2005;30:1127–33.